Jennifer Sullivan, PhD

Interim Provost and Dean of The Graduate School Augusta University

  • Augusta GA

Jennifer Sullivan, PhD, is an internationally recognized expert of sex differences in cardiovascular physiology and pathophysiology.

Contact

Augusta University

View more experts managed by Augusta University

Spotlight

5 min

AU research team awarded $4.4 million American Heart Association grant

A research team at Augusta University, led by Jennifer C. Sullivan, PhD, has secured a $4.4 million grant from the American Heart Association to study the risk factors for cardiovascular and kidney diseases and how they impact women. Sullivan’s research center, “Disruptions in cardiorenal free fatty acid metabolism in Cardiovascular Kidney Metabolic Syndrome,” is part of a larger $15 million project titled “Strategically Focused Research Network on Cardiovascular Kidney Metabolic Syndrome: Heterogeneity in Women.” The overarching AHA project is aimed at learning why women may be more likely to develop cardiovascular and kidney diseases due to certain unique risk factors and life stages. Research teams from Massachusetts General Hospital and The Ohio State University were also chosen. “I think this is a huge step for Augusta University as we continue to distinguish ourselves and the research that we have here focused on the health of women,” said Sullivan, dean of The Graduate School. “This grant is particularly impactful as we look to advance and improve the health of women, not just in Georgia, but for the entire country.” According to the Healthy Georgia Report, produced by AU’s School of Public Health, Georgia has the 23rd highest rate of obesity in the United States. Among the women living in the state, 38.3% of them, as well as 37.5% of people living in rural areas, suffer from obesity. “It’s great that we are able to represent the state of Georgia because our state has such a high prevalence for obesity rates,” said Sullivan, who is the director of AU’s SCORE project “Improving awareness of women with hypertension: ROAR (Rural, Obese, At Risk).” “It’s important for us to understand that different populations have distinct needs. You can’t talk about a one-size-fits-all approach to health. This is really about trying to understand how different groups are impacted.” Each center is comprised of three teams, as well as a training component and an area partner. Together, they will explore obesity’s lifetime impact on CKM syndrome through three projects. CKM syndrome is a clinical term that describes the combined health effects of heart disease, kidney disease, diabetes and obesity, which puts people at high risk for heart attack, stroke and heart failure. According to the American Heart Association’s 2025 Heart Disease and Stroke Statistics, about 1 in 3 U.S. adults has at least three components of CKM syndrome, which include high blood pressure, abnormal cholesterol, high blood glucose (sugar), impaired kidney function and excess body weight. The first project is led by Daria Ilatovskaya, PhD, and Justine Abais-Battad, PhD, and will look at aging and Western diet-induced CKMS mechanisms in obesity. Ilatovskaya is an associate professor and the graduate program director for the Doctor of Philosophy in Physiology program, and Abais-Battad is an assistant professor in the Department of Physiology with the Medical College of Georgia at Augusta University. The second component, led by Jessica Faulkner, PhD, an assistant professor in MCG’s Physiology department, will study obesity-associated mechanisms of CKMS in pregnancy. The third project, led by Stephen Coughlin, PhD, with Marlo Vernon, PhD, is looking at CKMS epidemiology, associations with obesity, CVD/CKD. Coughlin is the program director for the Master of Science in Epidemiology and professor of epidemiology in the School of Public Health’s Department of Biostatistics, Data Science, and Epidemiology, while Vernon is an associate professor with MCG’s Georgia Prevention Institute and SPH’s Department of Community and Behavioral Health Sciences. Additionally, the team will talk to women and health care providers from a variety of backgrounds and experiences to assess current knowledge and interest levels in heart health and use that information to develop programs that may help treat and prevent disease. There is also a training director, Alison Kriegel, PhD, a professor in the Department of Physiology, and a core director, Guido Verbeck, PhD, chair and professor of the Department of Chemistry and Biochemistry in the College of Science and Mathematics. “We have a strong blend of clinical epidemiology and basic science, as well as a training component, which we will fill with post-doctoral fellows,” Sullivan said. “Dr. Ilatovskaya, Dr. Faulkner, Dr. Abais-Battad and Dr. Vernon are all a part of our ROAR grant, and, while this isn’t directly related to that program, it allowed us to demonstrate how we are already well positioned to work together to amplify our ability and increase awareness about the importance of the health of women.” The team has over 50 collaborative papers and has secured more than $13 million in collaborative funding to advance the health of women. They also all have experience training fellows and students to continue to expand their reach. “We already have a lot of the infrastructure in place for this kind of cross-disciplinary project, so we leaned very heavily into our connections and the expertise we have here at Augusta University. It’s set up very similar to our ROAR program, so this is something that was really organic in nature,” Sullivan said. The American Heart Association has invested almost $300 million to establish 18 Strategically Focused Research Networks, each aimed at addressing a key strategic issue identified by the association’s volunteer Board of Directors. Prior networks have been studying a wide variety of important topics including, but not limited to, prevention, hypertension, the health of women, heart failure, obesity, vascular disease, atrial fibrillation, arrhythmias/sudden cardiac death, cardiometabolic health/type 2 diabetes, health technology, cardio-oncology, the biological impact of chronic psychosocial stress and the role of inflammation in cardiovascular health. Each network centers around scientific knowledge and knowledge gaps, prevention, diagnosis and treatment of the key research topic. Three to six research centers make up each network, bringing together investigators with expertise in basic, clinical and population/behavioral health science to find new ways to diagnose, treat and prevent heart disease and stroke. Funding scientific research and discovery through initiatives like these awards is a cornerstone of the century-old American Heart Association’s lifesaving mission. The association has now funded more than $5.9 billion in cardiovascular, cerebrovascular and brain health research since 1949, making it the single largest non-government supporter of heart and brain health research in the United States. New knowledge resulting from this funding continues to save lives and directly impact millions of people in every corner of the U.S. and around the world. Looking to know more about the amazing research happening at Augusta? To connect with Dr. Sullivan, simply click on her icon to arrange an interview today.

Jennifer Sullivan, PhDMarlo Vernon, PhD

Multimedia

Social

Biography

Jennifer Sullivan, PhD, has been a part of the AU community since 2000 when she joined the Vascular Biology Center in the Medical College of Georgia as a postdoctoral fellow.

She joined the faculty in 2008 and is currently a Regents Professor in the Department of Physiology, the Dean of the Graduate School, and the Interim EVP of Academic Affairs and Provost. Dr. Sullivan is an internationally recognized expert and leader in the field of sex differences in cardiovascular physiology and pathophysiology.

Dr. Sullivan's work has been continuously funded by the NIH and the American Heart Association since becoming a tenure track faculty member in 2008. She consistently publishes her work in the top journals in the field of hypertension, with over 120 peer reviewed articles and has received numerous prestigious awards for her outstanding work.

Dr. Sullivan has active leadership roles in national scientific societies, serves on the editorial board as associate editor for leading peer reviewed journals, and currently is chair of an NIH grant study section. She is also an exceptional educator and mentor, with a demonstrated commitment to the training of undergraduate, graduate, and medical students, as well as postdoctoral fellows and junior faculty members. She creates a challenging and collaborative training environment for all of her trainees while focusing on the needs of each individual.

Areas of Expertise

Hypertension
Cardiovascular Physiology
Pathophysiology
Higher Education Administration

Accomplishments

Harriet Dustan Award, American Heart Association Council on Hypertension

2024

Medical College of Georgia Outstanding Faculty Award

2024

Medical College of Georgia Group on Women in Medicine and Science (GWIMS) Leadership Award

2023

Show All +

Education

Albany Medical College

Ph.D.

Cardiovascular Technology/Technologist

2000

Albany Medical College

M.S.

Cardiovascular Technology/Technologist

1999

SUNY Geneseo

B.S.

Biology, General

1996

Affiliations

  • American Heart Association
  • American Physiological Society

Media Appearances

NIH training grant enhances opportunities for biomedical graduate students at AU

EurekAlert!  online

2021-04-12

The training grant enhances the caliber of the educational experience The Graduate School at AU provides students as it provides more dollars to pay an annual stipend to the students who are a critical biomedical workforce at a research university, says Dr. Jennifer Sullivan, interim dean of The Graduate School.

View More

New rodent model helps identify pregnant women whose prior kidney injury also affects babies

Medcal Life Sciences News  online

2021-02-22

We are talking about a population of young women that we usually think about as protected and healthy, and they are not if they have had a kidney insult. We think there is injury, potentially even years later, in some of these young women that we are not seeing, and we need to be able to quantify how much injury is still there."

View More

Females use anti-inflammatory T cells to keep their blood pressure down

Medical Xpress  online

2020-06-23

Females have an innate ability to upregulate these anti-inflammatory cells, called Tregs, in response to a challenge, says Dr. Jennifer C. Sullivan, pharmacologist and physiologist, noting that the cell's levels are known to increase to help maintain a healthy pregnancy, for example, so the immune system does not attack the fetus, which has DNA from both parents.

View More

Show All +

Articles

Adverse Maternal and Fetal Outcomes in a Novel Experimental Model of Pregnancy after Recovery from Renal Ischemia-Reperfusion Injury

Journal of the American Society of Nephrology

2021

Background: Recent clinical studies report that women with a history of AKI have an increased incidence of maternal and fetal adverse outcomes during pregnancy, despite fully recovering renal function prior to conception. The mechanisms contributing to such adverse outcomes in pregnancy after AKI are not yet understood.

Methods: To develop a rodent model to investigate fetal and maternal outcomes in female animals with a history of AKI, we used ischemia-reperfusion injury as an experimental model of AKI in female Sprague Dawley rats. The 12-week-old animals underwent warm bilateral ischemia-reperfusion surgery involving clamping of both renal arteries for 45 minutes or sham surgery (control). Rats were allowed to recover for 1 month prior to mating. Recovery from ischemia-reperfusion injury was confirmed by measurements of plasma creatinine and urinary protein excretion. We assessed maternal and fetal outcomes during late pregnancy on gestational day 20.

View more

Greater T Regulatory Cells in Females Attenuate DOCA-Salt-Induced Increases in Blood Pressure Versus Males

Hypertension

2020

Hypertension is the most common risk factor for cardiovascular disease, causing over 18 million deaths a year. Although the mechanisms controlling blood pressure (BP) in either sex remain largely unknown, T cells play a critical role in the development of hypertension. Further evidence supports a role for the immune system in contributing to sex differences in hypertension. The goal of the current study was to first, determine the impact of sex on the renal T-cell profiles in DOCA-salt hypertensive males and females and second, test the hypothesis that greater numbers of T regulatory cells (Tregs) in females protect against DOCA-salt-induced increases in BP and kidney injury. Male rats displayed greater increases in BP than females following 3 weeks of DOCA-salt treatment, although increases in renal injury were comparable between the sexes. DOCA-salt treatment resulted in an increase in proinflammatory T cells in both sexes; however, females had more anti-inflammatory Tregs than males. Additional male and female DOCA-salt rats were treated with anti-CD25 to decrease Tregs.

View more

Necrosis Contributes to the Development of Hypertension in Male, but Not Female, Spontaneously Hypertensive Rats

Hypertension

2019

Necrosis is a pathological form of cell death that induces an inflammatory response, and immune cell activation contributes to the development and maintenance of hypertension. Necrosis was measured in kidney, spleen, and aorta of 12- to 13-week-old male and female SHRs (spontaneously hypertensive rats); male SHRs had greater renal necrotic cell death than female SHRs. Because male SHRs have a higher blood pressure (BP) and a more proinflammatory T-cell profile than female SHRs, the current studies tested the hypothesis that greater necrotic cell death in male SHRs exacerbates increases in BP and contributes to the proinflammatory T-cell profile. Male and female SHRs were randomized to receive vehicle or Necrox-5-a cell permeable inhibitor of necrosis-from 6 to 12 weeks of age or from 11 to 13 weeks of age. In both studies, Necrox-5 decreased renal necrosis and abolished the sex difference. Treatment with Necrox-5 beginning at 6 weeks of age attenuated maturation-induced increases in BP in male SHR; BP in female SHR was not altered by Necrox-5 treatment. Necrox-5 decreased proinflammatory renal T cells in both sexes, although sex differences were maintained.

View more